Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335645 | 0.90 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL14143866 | 0.88 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL10219837 | 0.88 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL334455 | 0.86 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL333932 | 0.84 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL29293351 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL333717 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL334720 | 0.84 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2MAPTPPARG | |
| SCHEMBL24329835 | 0.80 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2MAPTPOLB | |
| SCHEMBL1729140 | 0.80 | PPARG (0.60) | NPC1RAB9ASMN1; SMN2MAPTPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-1939189-A1 | DERIVATIVE HAVING PPAR AGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | NPC1 1742/4885RAB9A 1784/4885SMN1; SMN2 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.